Skip NavigationSkip to Content

NCI at Frederick Scientific Publications Advanced Search

Search

  1. NCI-F Publications

  2. Return to Quick Search
Search
  2. Year Published:

Your search returned 17 results.
User Information
Export Records
  1. 1.   Stable Latent HIV Infection and Low-Level Viremia Despite Treatment with the Broadly Neutralizing Antibody VRC07-523LS and the Latency Reversal Agent Vorinostat
  2. Gay, C L; James, K S; Tuyishime, M; Falcinelli, S D; Joseph, S B; Moeser, M J; Allard, B; Kirchherr, J L; Clohosey, M; Raines, S L M; Montefiori, D C; Shen, X; Gorelick,Robert; Gama, L; McDermott, A B; Koup, R A; Mascola, J R; Floris-Moore, M; Kuruc, J D; Ferrari, G; Eron, J J; Archin, N M; Margolis, D M
  3. The Journal of Infectious Diseases. 2021, Sep 25;
  1. 2.   Carbohydrate antigen microarray analysis of serum IgG and IgM antibodies before and after adult porcine islet xenotransplantation in cynomolgus macaques
  2. Nanno, Yoshihide; Sterner, Eric; Gildersleeve,Jeffrey; Hering, Bernhard J.; Burlak, Christopher
  3. PLOS ONE. 2021, Jun 17; 16(6):
  1. 3.   A randomized trial of vorinostat with treatment interruption after initiating antiretroviral therapy during acute HIV-1 infection
  2. Kroon, Eugene D. M. D.; Ananworanich, Jintanat; Pagliuzza, Amelie; Rhodes, Ajantha; Phanuphak, Nittaya; Trautmann, Lydie; Mitchell, Julie L.; Chintanaphol, Michelle; Intasan, Jintana; Pinyakorn, Suteeraporn; Benjapornpong, Khuntalee; Chang, J. Judy; Colby, Donn J.; Chomchey, Nitiya; Fletcher, James L. K.; Eubanks, Keith; Yang, Hua; Kapson, John; Dantanarayana, Ashanti; Tennakoon, Surekha; Gorelick,Robert; Maldarelli, Frank; Robb, Merlin L.; Kim, Jerome H.; Spudich, Serena; Chomont, Nicolas; Phanuphak, Praphan; Lewin, Sharon R.; de Souza, Mark S.
  3. JOURNAL OF VIRUS ERADICATION. 2020, SEP; 6(3): 100004.
  1. 4.   RADX Promotes Genome Stability and Modulates Chemosensitivity by Regulating RAD51 at Replication Forks.
  2. Dungrawala, Huzefa; Bhat, Kamakoti P; Le Meur, Rémy; Chazin, Walter J; Ding, Xia; Sharan, Shyam; Wessel, Sarah R; Sathe, Aditya A; Zhao, Runxiang; Cortez, David
  3. Molecular cell. 2017, Aug 3; 67(3): 374-+.
  1. 5.   Mesoderm-specific Stat3 deletion affects expression of Sox9 yielding Sox9-dependent phenotypes
  2. Hall, Michael; Murray, Caroline A.; Valdez, Michael J.; Perantoni, Alan
  3. PLOS GENETICS. 2017, Feb 6; 13(2): e1006610.
  1. 6.   A Pharmacodynamic Study of Docetaxel in Combination with the P-glycoprotein Antagonist Tariquidar (XR9576) in Patients with Lung, Ovarian, and Cervical Cancer
  2. Kelly, R. J.; Draper, D.; Chen, C. C.; Robey, R. W.; Figg, W. D.; Piekarz, R. L.; Chen, X. H.; Gardner, E. R.; Balis, F. M.; Venkatesan, A. M.; Steinberg, S. M.; Fojo, T.; Bates, S. E.
  3. Clinical Cancer Research. 2011, Feb; 17(3): 569-580.
  1. 7.   IL-12 induced regression of orthotopic neuroblastoma tumors: Potential role for reversal of intrinsic mechanisms of resistance to tumor cell apoptosis
  2. Khan, T.; Hixon, J. A.; Stauffer, J. K.; Lincoln, E.; Back, T.; Wigginton, J. M.
  3. Clinical Cancer Research. 2003 9(16): 6227S-6227S.
  1. 8.   Progress toward clinical application of the nitric oxide- releasing diazeniumdiolates
  2. Keefer, L. K.
  3. Annual Review of Pharmacology and Toxicology. 2003 43: 585-607.
  1. 9.   Pervilleines B and C, new tropane alkaloid aromatic esters that reverse the multidrug-resistance in the hollow fiber assay
  2. Mi, Q. W.; Cui, B. L.; Silva, G. L.; Lantvit, D.; Lim, E.; Chai, H. Y.; Hollingshead, M. G.; Mayo, J. G.; Kinghorn, A. D.; Pezzuto, J. M.
  3. Cancer Letters. 2002 184(1): 13-20.
  1. 10.   Qualitative thin-layer and high-performance liquid chromatographic analysis of 1-substituted diazen-1-ium-1,2- diolates on aminopropyl-bonded silica gel
  2. Fitzhugh, A. L.; Anadu, N. O.; Waterhouse, D. J.; Hrabie, J. A.; Saavedra, J. E.; Keefer, L. K.
  3. Analytical Biochemistry. 2002 301(1): 97-102.
  1. 11.   Pervilleine A, a novel tropane alkaloid that reverses the multidrug-resistance phenotype
  2. Mi, Q. W.; Cui, B. L.; Silva, G. L.; Lantvit, D.; Lim, E.; Chai, H.; You, M.; Hollingshead, M. G.; Mayo, J. G.; Kinghorn, A. D.; Pezzuto, J. M.
  3. Cancer Research. 2001 61(10): 4030-4037.
  1. 12.   NO better pharmaceuticals
  2. Saavedra, J.; Keefer, L.
  3. Chemistry in Britain. 2000 36(7): 30-33.
  1. 13.   Identification of a novel Sry-related gene and its germ cell-specific expression
  2. Osaki, E.; Nishina, Y.; Inazawa, J.; Copeland, N. G.; Gilbert, D. J.; Jenkins, N. A.; Ohsugi, M.; Tezuka, T.; Yoshida, M.; Semba, K.
  3. Nucleic Acids Research. 1999 27(12): 2503-2510.
  1. 14.   Interaction of the P-glycoprotein multidrug transporter (MDR1) with high affinity peptide chemosensitizers in isolated membranes, reconstituted systems, and intact cells
  2. Sharom, F. J.; Yu, X. H.; Lu, P. H.; Liu, R. H.; Chu, J. W. K.; Szabo, K.; Muller, M.; Hose, C. D.; Monks, A.; Varadi, A.; Seprodi, J.; Sarkadi, B.
  3. Biochemical Pharmacology. 1999 58(4): 571-586.
  1. 15.   Development of heparin antagonists with focused biological activity
  2. Shenoy, S.; Sobel, M.; Harris, R. B.
  3. Current Pharmaceutical Design. 1999 5(12): 965-986.
  1. 16.   Resistance to Paclitaxel Mediated By P-Glycoprotein Can Be Modulated By Changes in the Schedule of Administration
  2. Zhan, A. R.; Scala, S.; Monks, A.; Hose, C.; Bates, S.; Fojo, T.
  3. Cancer Chemotherapy and Pharmacology. 1997 40(3): 245-250.
  1. 17.   Chemoprevention of Spontaneous Tumorigenesis in Nullizygous P53-Deficient Mice By Dehydroepiandrosterone and Its Analog 16-Alpha-Fluoro-5-Androsten-17-One
  2. Perkins, S. N.; Hursting, S. D.; Haines, D. C.; James, S. J.; Miller, B. J.; Phang, J. M.
  3. Carcinogenesis. 1997 18(5): 989-994.
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel